攝護腺癌淋巴轉移使用放射賀爾蒙合併治療之分析: 單一醫院經驗
方楚文1、劉建良1、黃冠華1、沈坤宏1、陳俊豪、蘇家震1、王致丞1、林奎利2、麥志輝3
1奇美醫療財團法人奇美醫學中心1外科部泌尿外科, 2放射腫瘤部, 3影像醫學部
The results of combined radiation therapy and hormonal therapy in the treatment of Lymph node-positive prostate cancer: experience of a single Institution
Chu-Wen Fang1, Chien Liang Liu1, Steven Kuan-Hua Huang1, Kun-Hung Shen1, Chun-Hao Chen, Chia-Cheng Su1, Jhih-Cheng Wang1, Kuei-Li Lin2, Chee-Wai Mak3
1Division of Urology, Department of Surgery, 2Department of Radiation Oncology, and 3Department of Radiology, Chi Mei Medical Center, Tainan, Taiwan
 
Purpose
To evaluate OS and CSM after combined hormonal-radiationtherapy of adenocarcinoma of the prostate and to measure the survival in a group of patients with radiographically pelvic lymph nodes metastases.
Materials & Methods
From 2011 to 2015, 38 patients with adenocarcinoma of the prostate with radiographically pelvic lymph node involvement were treated with combined radiation therapy and hormonal therapy. Patients treated with combined therapy include 2 patients with T1 tumors, 3 patients with T2, 27 patients with T3, 6 patients with T4.
Hormonal therapy continued for 2-3 years.
Result
Median follow-up is 48.1 months. The 5 year overall survival was 69.4% and CSS 76.4%, Factors independently associated with increased CSM were cT4 disease and PSA> 20 ng/ml….
Conclusion
Our data showed good OS and CSS as treated with ADT+ RT without severe toxicity. Prospective randomized trials are needed to confirm the long-term outcomes and toxicity profile of these treatment approaches.
    位置
    資料夾名稱
    摘要
    發表人
    TUA人資客服組
    單位
    台灣泌尿科醫學會
    建立
    2019-07-07 21:15:33
    最近修訂
    2019-07-07 21:16:21
    更多